title: Economic impact of hypoglycemia on healthcare in Spain.
abstract: Diabetes mellitus has a major impact on costs for healthcare and society. The estimation for 2010 is that investment in diabetes will reach 11.6% of public healthcare expenses worldwide. The expected rise in the prevalence of diabetes over the coming decades may create problems for the sustainability of healthcare systems, such as those in Spain. The rise in direct costs is the main issue in diabetes, especially the treatment of acute and chronic complications that often need hospital care. Severe hypoglycemia (SH) is the most frequent acute complication. In Spain, the incidence of SH is estimated at two episodes per patient per year for Type 1 diabetes and one to two episodes for advanced Type 2 diabetes requiring insulin treatment. Although results vary, Spanish national data provide an estimated cost of approximately €3500 per SH episode. It also has a major influence on indirect costs, mainly related to reduced productivity, absenteeism and occasionally early retirement, and affects direct health, such as quality of life. As a result of SH, patients acquire a fear of new hypoglycemic episodes, which makes them modify their behavior and habits and, in the long term, has the potential to negatively impact metabolic control. Educational programs for healthcare professionals and patients with diabetes, increased involvement of patients in the management of their illness and regular self-measurement of blood glucose are all strategies aimed at minimizing the social and economic effects of severe hypoglycemia.
authors.affiliation: Servicio de Endocrinología y Nutrición, Hospital Universitario Puerta de Hierro Majadahonda (Madrid), C/ Manuel de Falla, 1 Majadahonda 28220, Madrid, Spain.
authors.forename: M
authors.initials: M
authors.lastname: Brito-Sanfiel
authors.forename: J
authors.initials: J
authors.lastname: Diago-Cabezudo
authors.forename: A
authors.initials: A
authors.lastname: Calderon
mesh_terms: D003922:Diabetes Mellitus, Type 1 / Q000188:drug therapy / Q000191:economics* / Q000453:epidemiology; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy / Q000191:economics* / Q000453:epidemiology; D017048:Health Care Costs / Q000706:statistics & numerical data* / Q000639:trends; D006801:Humans; D007003:Hypoglycemia / Q000191:economics* / Q000453:epidemiology / Q000209:etiology; D007004:Hypoglycemic Agents / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use; D007328:Insulin / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use; D015995:Prevalence; D012720:Severity of Illness Index; D013030:Spain / Q000453:epidemiology
chemical_list: D007004:Hypoglycemic Agents; D007328:Insulin